The Latest Cardiac and Vascular News
-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery- –RBT-1 treatment demonstrated a statistically significant reduction in ICU days and 30-day cardiopulmonary readmission rates; patients treated with RBT-1 had reduced time on […]
— Full results published in European Heart Journal Open — — Study met primary safety endpoint — — All patients alive, transplant-free, and maintained expected rate of growth one year after treatment — — Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial — […]
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier […]
Abbott’s new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation (TAVI) offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease ABBOTT PARK, Ill., Jan. 17, 2023 /PRNewswire/ — […]
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, announced today that the first patient has enrolled in the REAL SSO2 post-market observational study to assess the clinical utility and cost-effectiveness of TherOx SuperSaturated Oxygen (SSO2) Therapy compared to PCI alone in standard of care treatment for ST-elevation myocardial infarction (STEMI) patients. The […]
— Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) — — Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm — — Favorable safety and tolerability — — Data support advancement of fixed-dose combination into bioequivalence and Phase 3 […]
Triglyceride-rich LDL particles were found to be directly causal in ASCAD based on Aitia’s Digital Twins built on G3’s Global Multi-omic Clinical Study Data and Aitia’s Causal AI Technology LDL-Triglycerides may become an important diagnostic biomarker in ASCAD and may lead to new therapeutics ATLANTA and SOMERVILLE, Mass., Jan. 12, 2023 /PRNewswire/ — G3 […]
Timely Home-Based Treatment Creates Pathway to Reduce the National 25% Average for Hospital Re-Admissions Down to Just 6.8% SPOKANE, Wash. and DENVER, Jan. 12, 2023 /PRNewswire/ — Known for a solid commitment to advancing heart and vascular medicine in the Pacific Northwest, MultiCare’s Pulse Heart Institute set out to change the narrative for congestive heart failure patients […]
GENT, Belgium–(BUSINESS WIRE)–FEops announces Euan S. Thomson, PhD has been appointed as new Chairman. Euan Thomson succeeds veteran medical device executive Rob Michiels, who continues to support FEops as an independent board member. FEops has made significant progress with rollout of their HEARTguide structural heart planning software based on digital twin […]
Research collaboration to target severe form of genetic dilated cardiomyopathy Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapy Collaboration allows Phlox Therapeutics to leverage Solid Biosciences’ vector biology and manufacturing capacities to deliver its RNA therapies to the heart CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. […]
